Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

India's Hep-C Market: The Old Order Changeth?

This article was originally published in Scrip

Executive Summary

Is peginterferon alfa 2b potentially heading for near obsolescence on the Indian market as a therapy for hepatitis C virus (HCV) infection, now with the availability of cut-price sofosbuvir versions? Probably yes, if a clutch of industry pundits are to be believed and going by some market-related activity or indeed the lack of it.



Related Companies